{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T06:09:57Z","timestamp":1770703797314,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jfo.2016.05.014","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T20:46:06Z","timestamp":1502397966000},"page":"547-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inefficacit\u00e9 de l\u2019aflibercept dans le traitement des t\u00e9langiectasies maculaires idiopathiques de type 2\u00a0sans n\u00e9ovascularisation"],"prefix":"10.1016","volume":"40","author":[{"given":"J.","family":"B\u00e9nichou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Matonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2016.05.014_bib0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/IAE.0b013e3181bd2c71","article-title":"The prevalence estimates of macular telangiectasia type 2: the Melbourne Collaborative Cohort Study","volume":"30","author":"Aung","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2016.05.014_bib0060","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0161-6420(93)31447-8","article-title":"Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study","volume":"100","author":"Gass","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2016.05.014_bib0065","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/archopht.124.4.450","article-title":"Idiopathic maculat telangiectasia","volume":"124","author":"Yannuzzi","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2016.05.014_bib0070","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/bjo.2007.129627","article-title":"Eighteen-month follow-up of intravitreal bevacizumab in type 2\u00a0idiopathic macular telangiectasia","volume":"92","author":"Charbel Issa","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2016.05.014_bib0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/IAE.0b013e31818ba9de","article-title":"Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II","volume":"29","author":"Kovach","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2016.05.014_bib0080","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/archophthalmol.2010.155","article-title":"Intravitreous ranibizumab as treatment for macular telangiectasiatype 2","volume":"128","author":"Lira","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jfo.2016.05.014_bib0085","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ajo.2010.11.019","article-title":"Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study","volume":"151","author":"Charbel Issa","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2016.05.014_bib0090","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/IAE.0b013e31824690a8","article-title":"Treatment of nonneovascular idiopathic macular telangiectasia type 2\u00a0with intravitreal ranibizumab: results of a phase II clinical trial","volume":"32","author":"Toy","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2016.05.014_bib0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000346130","article-title":"Intravitreal bevacizumab for type 2\u00a0idiopathic macular telangiectasia","volume":"49","author":"Veloso","year":"2013","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.jfo.2016.05.014_bib0050","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/IAE.0000000000000203","article-title":"Ranibizumab for macular telangiectasia type 2\u00a0in the absence of subretinal neovascularization","volume":"34","author":"Do","year":"2014","journal-title":"Retina"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551217302292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551217302292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:07:15Z","timestamp":1759259235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551217302292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0181551217302292"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2016.05.014","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inefficacit\u00e9 de l\u2019aflibercept dans le traitement des t\u00e9langiectasies maculaires idiopathiques de type 2\u00a0sans n\u00e9ovascularisation","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2016.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}